Clinical Trials Using LSD1 Inhibitor IMG-7289

Clinical trials are research studies that involve people. The clinical trials on this list are studying LSD1 Inhibitor IMG-7289. All trials on the list are supported by NCI.

NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.

Trials 1-4 of 4
  • IMG-7289 in Patients With Myelofibrosis

    This is a Phase 2b open label study of an orally administered LSD1 inhibitor, IMG-7289, in patients with myelofibrosis. This study investigates the following: - The safety and tolerability of IMG-7289 - The pharmacokinetics of IMG-7289 (performed in Phase 1 / 2a only) - The pharmacodynamic effect of IMG-7289
    Location: 8 locations

  • An Enzyme Inhibitor, IMG-7289 for the Treatment of Essential Thrombocythemia or Polycythemia Vera That Has Failed at Least One Standard Therapy

    This phase II trial studies the side effects and how well IMG-7289 works in treating patients with essential thrombocythemia or polycythemia vera that has not responded adequately to standard therapies. IMG-7289, is a new oral (taken by mouth) medication that works by turning off the activity of an enzyme called LSD1 (lysine specific demethylase 1) which is present at low levels in cells of all people. High levels of LSD1 inside the abnormal stem cells of essential thrombocythemia or polycythemia vera patients are believed to block the cells from becoming mature cells that function normally; instead, the abnormal cells continue to be made. This, in turn, lowers the abnormal red cell and platelet counts seen in patients with essential thrombocythemia or polycythemia vera.
    Location: University of Miami Miller School of Medicine-Sylvester Cancer Center, Miami, Florida

  • IMG-7289 in Patients With Essential Thrombocythemia

    This is a Phase 2b open label study of an orally administered LSD1 inhibitor, IMG-7289, in patients with essential thrombocythemia. This study investigates the following: - The safety and tolerability of IMG-7289 - The pharmacodynamic effect of IMG-7289
    Location: 2 locations

  • LSD1 Inhibitor IMG-7289 for the Treatment of Essential Thrombocythemia

    This phase II trial studies how well LSD1 inhibitor IMG-7289 works for the treatment of essential thrombocythemia. LSD1 inhibitor IMG-7289 works by turning off the activity of an enzyme called LSD1 (lysine-specific demethylase 1) which is present at low levels in cells of all people. High levels of LSD1 inside the abnormal stem cells of essential thrombocythemia patients are believed to block the cells from becoming mature cells that function normally; instead, the abnormal cells continue to be made. This, in turn, lowers the abnormal red cell and platelet counts seen in patients with essential thrombocythemia. LSD1 inhibitor IMG-7289 may decrease spleen size and other inflammatory markers which are believed to cause symptoms in these diseases.
    Location: Cancer Therapy and Research Center at The UT Health Science Center at San Antonio, San Antonio, Texas